| Field | Specification |
|---|---|
| Target | |
| Alternative names | Cytotoxic T-lymphocyte protein 4;Cytotoxic T-lymphocyte-associated antigen 4;CTLA-4;CD152;Ctla4;Cd152; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E. coli-derived mouse CTLA4 recombinant protein (Position: E36-D161). Mouse CTLA4 shares 67.5% amino acid (aa) sequence identity with human CTLA4. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets cytotoxic T-lymphocyte protein 4 (gene Ctla4) in mouse and rat samples and is validated for ELISA, IHC and Western blot. The predicted molecular weight is 25.0 kDa, and the supplier reports an observed band at about 25 kDa.
CTLA-4 (CD152) is an inhibitory receptor on activated T cells and regulatory T cells that dampens T-cell responses. It binds the B7 ligands CD80 and CD86 with much higher affinity than the costimulatory receptor CD28, competing with CD28 for these ligands and limiting activation. CTLA-4 is a key immune checkpoint studied in autoimmunity, tolerance and cancer immunotherapy.
| Target | Cytotoxic T-lymphocyte protein 4 (gene Ctla4; UniProt P09793, mouse) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 25.0 kDa |
| Observed MW | 25 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Mouse) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Mouse, Rat) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): mouse NIH3T3 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): mouse spleen tissue, rat lymphaden tissue, rat spleen tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Immunogen
Recombinant mouse CTLA4 fragment (Glu36–Asp161), expressed in E. coli. Sequence identity with the human ortholog: 67.5%.
Reactivity Notes
The supplier lists reactivity with mouse and rat. UniProt places cytotoxic T-lymphocyte protein 4 in the cell membrane. Tissue expression noted by UniProt (mouse): Widely expressed with highest levels in lymphoid tissues. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Gao Liyun et al. (2025) Identification of m6A methyltransferase-related WTAP and ZC3H13 predicts immune infiltrates in glioblastoma. Scientific Reports. 10.1038/s41598-025-88671-4
Chi Wei et al. (2022) Effects of Nivolumab and Ipilimumab on the suppression of cisplatin resistant small cell lung cancer cells. Investigational New Drugs. 10.1007/s10637-022-01243-5
